US 11,865,226 B2
Cardiovascular prostheses
Robert G Matheny, Norcross, GA (US)
Assigned to CorMatrix Cardiovascular, Inc., Roswell, GA (US)
Filed by CorMatrix Cardiovascular, Inc., Roswell, GA (US)
Filed on Nov. 5, 2020, as Appl. No. 17/089,888.
Application 15/877,586 is a division of application No. 15/386,640, filed on Dec. 21, 2016, granted, now 10,143,778, issued on Dec. 4, 2018.
Application 17/089,888 is a continuation of application No. 16/531,263, filed on Aug. 5, 2019, abandoned.
Application 16/531,263 is a continuation of application No. 15/877,586, filed on Jan. 23, 2018, granted, now 10,383,977, issued on Aug. 20, 2019.
Application 15/386,640 is a continuation in part of application No. 13/328,287, filed on Dec. 16, 2011, granted, now 9,532,943, issued on Jan. 3, 2017.
Prior Publication US 2021/0046216 A1, Feb. 18, 2021
Int. Cl. A61L 27/36 (2006.01); A61F 2/00 (2006.01); A61K 31/4418 (2006.01); A61L 27/34 (2006.01); A61L 27/38 (2006.01); A61L 27/54 (2006.01); A61L 27/58 (2006.01); A61F 2/06 (2013.01); A61L 27/50 (2006.01)
CPC A61L 27/3633 (2013.01) [A61F 2/00 (2013.01); A61F 2/0095 (2013.01); A61F 2/06 (2013.01); A61K 31/4418 (2013.01); A61L 27/34 (2013.01); A61L 27/3834 (2013.01); A61L 27/507 (2013.01); A61L 27/54 (2013.01); A61L 27/58 (2013.01); A61F 2210/0004 (2013.01); A61F 2250/0067 (2013.01); A61L 2300/414 (2013.01); A61L 2430/20 (2013.01)] 1 Claim
OG exemplary drawing
 
1. A cardiovascular prosthesis, consisting of:
an Extracellular Matrix (ECM)-mimicking composition consisting of a plurality of particulate structures, each of said plurality of particulate structures consisting of poly(glycerol sebacate) (PGS), cerivastatin and everolimus, said cerivastatin is present in an amount of 0.01 wt. % to 0.1 wt. % of said ECM-mimicking composition, said everolimus is present in an amount of 0.001 wt. % to 0.01 wt. % of said ECM-mimicking composition,
wherein said plurality of particulate structures are adapted to modulate inflammation of damaged cardiovascular tissue in vivo by increasing expression of Kruppel like factor 2 (KLF-2), whereby localized expression of monocyte chemoattractant protein 1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) is inhibited at transcriptional and translational levels as a function of said increased expression of said KLF-2.